The FDA Let Flavored Vapes Back In. Its Own Enforcement Staff Didn't See It Coming.

On May 22, the FDA authorized four flavored e-cigarettes for sale in the United States and issued guidance allowing flavored nicotine pouches to remain on store shelves while under review. The flavors include mango and blueberry. The guidance was posted days before the former FDA Commissioner resigned. The agency’s staff responsible for enforcing vaping regulations were not consulted before the decision was announced.

That last detail is the one that deserves more attention than it’s getting.

FDA enforcement staff — the people who issue warning letters, inspect retailers, and track unauthorized products — learned about the policy shift the same way everyone else did: by reading it. According to CNN’s reporting, senior officials were blindsided. This wasn’t a regulatory process failure. It was a sign that the decision was made outside the usual channels, in a way that suggests the outcome was predetermined and the staff consultation was skipped because it wasn’t going to produce the desired result.

The context matters here: 1.6 million American kids were current e-cigarette users in 2024. Of the middle and high school students who reported vaping in the past month, one in four did so daily. Close to 88 percent of kids who vape use flavored products; 62.8 percent specifically choose fruit flavors. Nicotine pouches are the only tobacco product that has been increasing in use among young people over the past five years, while other categories decline.

The FDA has spent the last decade building a regulatory framework that treated flavored products as a specific risk vector for youth nicotine addiction. That framework wasn’t perfect — enforcement was chronically underfunded and the authorization backlogs were measured in years — but the policy rationale was sound: fruit and candy flavors make nicotine products appealing to young palates in ways that unflavored or tobacco-flavored products don’t. Mango Juul was not an accident.

What changed in May wasn’t the evidence. The CDC’s data on youth vaping rates is what it is. The science on nicotine’s effects on the adolescent brain — interrupting prefrontal cortex development, creating lasting changes in reward circuitry, establishing dependence patterns that persist decades later — hasn’t shifted. What changed was who was deciding.

The American Lung Association described the May decisions as putting youth at risk, noting that flavored products are the primary driver of youth initiation. STAT News reported in March that an earlier round of guidance on flavored vapes had already sparked concerns about regulatory capture within the Center for Tobacco Products.

The long-term policy consequence of this pattern — staff not consulted, guidance issued as commissioners resign, flavors back on the market — is that the regulatory infrastructure for tobacco products loses institutional credibility. Rebuilding it takes years. The nicotine addiction it enables in the meantime is not reversible on the same timeline. A kid who starts vaping mango-flavored nicotine at 14 doesn’t benefit from a policy correction at 19.

For the treatment and harm-reduction community, nicotine addiction doesn’t get the attention it deserves because it doesn’t kill people quickly enough to dominate the crisis narrative. But nicotine is the most common co-occurring substance use disorder among people seeking treatment for alcohol or other drugs, and its presence complicates treatment outcomes. Treating it as a low-stakes issue because the mortality curve is longer is a category error the FDA just made structural.